Keith Jones

Find an error

Name:
Organization: The Institute of Cancer Research
Department: Division of Cancer Therapeutics
Title:
Co-reporter:Matthew D. Cheeseman;Nicola E. A. Chessum;Susan Lepri;Birgit Wilding;Carl S. Rye;Lindsay E. Evans;A. Elisa Pasqua;Meirion Richards;Robert te Poele;Swee Y. Sharp;Angela Hayes;Marissa Powers;Rosemary Burke;Michael J. Tucker;Martin Rowlands;Emmanuel De Billy;Loredana Pellegrino;Salyha Ali;Rob L. M. van Montfort;Lisa O’Fee;Florence Raynaud;Asadh Miah;Alan T. Henley;Suzanne A. Eccles;Paul Workman
Journal of Medicinal Chemistry January 12, 2017 Volume 60(Issue 1) pp:180-201
Publication Date(Web):November 23, 2016
DOI:10.1021/acs.jmedchem.6b01055
Phenotypic screens, which focus on measuring and quantifying discrete cellular changes rather than affinity for individual recombinant proteins, have recently attracted renewed interest as an efficient strategy for drug discovery. In this article, we describe the discovery of a new chemical probe, bisamide (CCT251236), identified using an unbiased phenotypic screen to detect inhibitors of the HSF1 stress pathway. The chemical probe is orally bioavailable and displays efficacy in a human ovarian carcinoma xenograft model. By developing cell-based SAR and using chemical proteomics, we identified pirin as a high affinity molecular target, which was confirmed by SPR and crystallography.
Co-reporter:Matthew D. Cheeseman; Isaac M. Westwood; Olivier Barbeau; Martin Rowlands; Sarah Dobson; Alan M. Jones; Fiona Jeganathan; Rosemary Burke; Nadia Kadi; Paul Workman; Ian Collins; Rob L. M. van Montfort
Journal of Medicinal Chemistry 2016 Volume 59(Issue 10) pp:4625-4636
Publication Date(Web):April 27, 2016
DOI:10.1021/acs.jmedchem.5b02001
HSP70 is a molecular chaperone and a key component of the heat-shock response. Because of its proposed importance in oncology, this protein has become a popular target for drug discovery, efforts which have as yet brought little success. This study demonstrates that adenosine-derived HSP70 inhibitors potentially bind to the protein with a novel mechanism of action, the stabilization by desolvation of an intramolecular salt-bridge which induces a conformational change in the protein, leading to high affinity ligands. We also demonstrate that through the application of this mechanism, adenosine-derived HSP70 inhibitors can be optimized in a rational manner.
Co-reporter:Carl S. Rye, Nicola E. A. Chessum, Scott Lamont, Kurt G. Pike, Paul Faulder, Julie Demeritt, Paul Kemmitt, Julie Tucker, Lorenzo Zani, Matthew D. Cheeseman, Rosie Isaac, Louise Goodwin, Joanna Boros, Florence Raynaud, Angela Hayes, Alan T. Henley, Emmanuel de Billy, Christopher J. Lynch, Swee Y. Sharp, Robert te Poele, Lisa O’ Fee, Kevin M. Foote, Stephen Green, Paul Workman and Keith Jones  
MedChemComm 2016 vol. 7(Issue 8) pp:1580-1586
Publication Date(Web):13 Jun 2016
DOI:10.1039/C6MD00159A
Heat shock factor 1 (HSF1) is a transcription factor that plays key roles in cancer, including providing a mechanism for cell survival under proteotoxic stress. Therefore, inhibition of the HSF1-stress pathway represents an exciting new opportunity in cancer treatment. We employed an unbiased phenotypic screen to discover inhibitors of the HSF1-stress pathway. Using this approach we identified an initial hit (1) based on a 4,6-pyrimidine scaffold (2.00 μM). Optimisation of cellular SAR led to an inhibitor with improved potency (25, 15 nM) in the HSF1 phenotypic assay. The 4,6-pyrimidine 25 was also shown to have high potency against the CDK9 enzyme (3 nM).
Co-reporter:Colin W. Robinson, Carl S. Rye, Nicola E. A. Chessum and Keith Jones  
Organic & Biomolecular Chemistry 2015 vol. 13(Issue 27) pp:7402-7407
Publication Date(Web):12 Jun 2015
DOI:10.1039/C5OB00886G
β-Sheet mediated protein–protein interactions are involved in key signalling pathways in diseases such as cancer. We present small molecule β-strand mimetics and investigate their interactions with a model tripeptide. Using 1H NMR, the thermodynamic parameters for their binding are determined. These give insight into this biologically important interaction.
Co-reporter:Jennie A. Hickin, Afshan Ahmed, Katharina Fucke, Margaret Ashcroft and Keith Jones  
Chemical Communications 2014 vol. 50(Issue 10) pp:1238-1240
Publication Date(Web):09 Dec 2013
DOI:10.1039/C3CC48189A
The synthesis of emetine analogue NSC-134754, a potent inhibitor of the HIF pathway, has been accomplished and its structure reassigned. The stereochemistry of NSC-134754 has been assigned for the first time using X-ray crystallography and it has been demonstrated that only one diastereoisomer is active against HIF.
Co-reporter:Matthew D. Cheeseman, Amir Faisal, Sydonia Rayter, Olivier R. Barbeau, Andrew Kalusa, Maura Westlake, Rosemary Burke, Michael Swan, Rob van Montfort, Spiros Linardopoulos, Keith Jones
Bioorganic & Medicinal Chemistry Letters 2014 Volume 24(Issue 15) pp:3469-3474
Publication Date(Web):1 August 2014
DOI:10.1016/j.bmcl.2014.05.067
Co-reporter:Lindsay E. Evans, Matthew D. Cheeseman, and Keith Jones
Organic Letters 2012 Volume 14(Issue 13) pp:3546-3549
Publication Date(Web):June 26, 2012
DOI:10.1021/ol301561a
An efficient one-pot synthesis of N-aryl[3,4-d]pyrazolopyrimidines in good yield and under mild reaction conditions is described. By exploiting electron-deficient hydroxylamines, the substituted oxime products were formed with very high E-diastereoselectivity. The key step utilizes a cyclization reaction upon an oxime derived from hydroxylamine-O-sulfonic acid to form the N–N bond of the product.
Co-reporter:Nadia M. Ahmad, Keith Jones
Tetrahedron Letters 2010 Volume 51(Issue 25) pp:3263-3265
Publication Date(Web):23 June 2010
DOI:10.1016/j.tetlet.2010.04.052
A series of thiazolo[3,2-a]pyrimidinones was synthesised in a two-step procedure, using Eaton’s reagent to effect cyclisation of 2-aminothiazoles. The use of relatively low temperatures, facile product isolation and short reaction times make this cyclisation procedure a particularly attractive option over more conventional methods.
Co-reporter:Sharon Rossiter, Jean-Marie Péron, Philip J. Whitfield, Keith Jones
Bioorganic & Medicinal Chemistry Letters 2005 Volume 15(Issue 21) pp:4806-4808
Publication Date(Web):1 November 2005
DOI:10.1016/j.bmcl.2005.07.044
2,4-Disubstituted quinolines with additional substituents in positions 5–8 have been found to have anthelmintic properties. A number of 2,4-dimethoxy-6- or 8-arylquinolines have potent activity against the sheep nematode Haemonchus contortus, with LD99 values of the same order of magnitude as levamisole. These arylquinolines maintain their activity against levamisole-, ivermectin- and thiabendazole-resistant strains of H. contortus.A number of aryl-substituted 2,4-dimethoxyquinolines have been synthesized and tested against a range of nematodes. The 6-substituted compounds show significant activity against resistant strains.
Co-reporter:Colin W. Robinson, Carl S. Rye, Nicola E. A. Chessum and Keith Jones
Organic & Biomolecular Chemistry 2015 - vol. 13(Issue 27) pp:NaN7407-7407
Publication Date(Web):2015/06/12
DOI:10.1039/C5OB00886G
β-Sheet mediated protein–protein interactions are involved in key signalling pathways in diseases such as cancer. We present small molecule β-strand mimetics and investigate their interactions with a model tripeptide. Using 1H NMR, the thermodynamic parameters for their binding are determined. These give insight into this biologically important interaction.
Co-reporter:Jennie A. Hickin, Afshan Ahmed, Katharina Fucke, Margaret Ashcroft and Keith Jones
Chemical Communications 2014 - vol. 50(Issue 10) pp:NaN1240-1240
Publication Date(Web):2013/12/09
DOI:10.1039/C3CC48189A
The synthesis of emetine analogue NSC-134754, a potent inhibitor of the HIF pathway, has been accomplished and its structure reassigned. The stereochemistry of NSC-134754 has been assigned for the first time using X-ray crystallography and it has been demonstrated that only one diastereoisomer is active against HIF.
2-AMINO-3-METHYLCYCLOBUTANOL
SCH727965
2-Propen-1-ol, 2-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-
3H-Indolium, 2-[5-[1-[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene]-1,3-pentadien-1-yl]-1-ethyl-3,3-